Abstracts

Poster-Disease-modifying Therapy

Does Frequency and Severity of COVID-19 Differ By Disease Modifying Therapy in MS Patients?

Background: Some authors have reported positive associations between B-cell-depleting (anti-CD20) therapies and COVID-19 infection risk or...

Read More

Poster-Disease-modifying Therapy

COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths

Background: Emerging data from people with multiple sclerosis (PwMS) suggest that some disease-modifying therapies (DMTs) may impact the...

Read More

Poster-Disease-modifying Therapy

Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data

Background: The efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. This analysis provides the first account...

Read More

Poster-Disease-modifying Therapy

Psoriasis in Multiple Sclerosis Patients Treated with Disease Modifying Therapies

Background: Psoriasis may be more common in people living with multiple sclerosis (PwMS) than in the general population. Some pathways...

Read More

Poster-Disease-modifying Therapy

Dual Mode of Action of Siponimod in Secondary Progressive Multiple Sclerosis: A Hypothesis Based on the Relevance of Pharmacological Properties

Background: Siponimod, a potent and selective sphingosine 1-phosphate (S1P1,5) receptor modulator, is the first oral disease-modifying...

Read More

Poster-Disease-modifying Therapy

Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem

Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefit–risk profile in patients with relapsing-remitting...

Read More

Poster-Disease-modifying Therapy

Natalizumab: Management and Safety during the COVID-19 Pandemic

Background: MS patients treated with monoclonal antibodies have an increased risk of infections. Natalizumab (NTZ) is a monoclonal antibody...

Read More

Poster-Disease-modifying Therapy

Evaluating Perceptions of Ofatumumab in Multiple Sclerosis Via Social Media Listening – Early 3 Months Post Approval Data

Background: Superior efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. Objectives: The social media...

Read More

Poster-Disease-modifying Therapy

Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study

Background: Siponimod is a selective S1P receptor (S1P1 and S1P5) modulator, approved in the USA for treatment of relapsing forms of MS,...

Read More

Poster-Disease-modifying Therapy

Assessing the Impact of Fingolimod Adherence on Relapse and Costs Using Marginal Structural Models

Background: Disease modifying therapies (DMTs) for relapsing MS are most effective when patients adhere to them as prescribed. Published...

Read More